Latest News for: asco

Edit

Amplia Therapeutics to Present at 2026 ASCO Gastrointestinal Cancers Symposium (Amplia Therapeutics Ltd)

Public Technologies 23 Dec 2025
). The text version of this document is not available ... Disclaimer ... (noodl. 128599470) .
Edit

Amplia Therapeutics to Present at 2026 ASCO Gastrointestinal Cancers Symposium

Hastings Tribune 23 Dec 2025
... ASCO Gastrointestinal Cancers Symposium, being .
Edit

Next chapter for ASCO in a shifting world

Energy Voice 19 Dec 2025
Having launched a 'bolder, better brand' putting one name on the businesses across the world, CEO Mike Pettigrew reflects on achievements and challenges ....
Edit

Astellas to Present New Clinical Data Across Its Gastrointestinal Cancers Portfolio at 2026 ASCO GI ...

Ravalli Republic 11 Dec 2025
- Data reflect new insights and precision oncology advancements in portfolio and pipeline - ... .
Edit

RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026

Nasdaq Globe Newswire 11 Dec 2025
The Accepted Abstract Provides Supportive Evidence for the TAMP™ Therapy ...
Edit

Astellas to Present New Clinical Data Across Its Gastrointestinal Cancers Portfolio at 2026 ASCO GI Cancers Symposium

PR Newswire 10 Dec 2025
... at the 2026 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium taking place January 8-10, 2026 in San Francisco, California ... Astellas Presentations at ASCO GI 2026.
Edit

Phanes Therapeutics to Present Phase 1/2 Study Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline (1L) Treatment of Metastatic PDAC at ASCO GI 2026

PR Newswire 09 Dec 2025
... treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium held on Jan 8-10, 2026 in San Francisco, CA.
Edit

Zenocutuzumab-zbco (BIZENGRI®) Shows Durable Efficacy in Patients with Treatment-Naïve NRG1+NSCLC: Updated eNRGy Trial Results Presented at IASLC-ASCO NACLC

PR Newswire 06 Dec 2025
LEXINGTON, Mass., Dec ... Results were presented in a late-breaking oral session at the IASLC-ASCO North America Conference on Lung Cancer (NACLC), in Chicago, Illinois ... Additional meeting information can be found on the IASLC-ASCO NACLC website ... 21% ... .
Edit

Alpha Tau Announces Presentation of Two Alpha DaRT Pancreatic Cancer Abstracts at Upcoming 2026 ASCO ...

Nasdaq Globe Newswire 04 Dec 2025
Pancreatic cancer multi-center clinical trial in U.S.
Edit

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ASCO Gastrointestinal Cancers Symposium

Nasdaq Globe Newswire 04 Dec 2025
ASCO-GI has announced that it will release further details for regular abstracts for the conference on January 5, 2026.
Edit

Alpha Tau Announces Presentation of Two Alpha DaRT Pancreatic Cancer Abstracts at Upcoming 2026 ASCO GI Symposium (Form 6-K) (Alpha Tau Medical Ltd)

Public Technologies 04 Dec 2025
Alpha Tau Announces Presentation of Two Alpha DaRT Pancreatic Cancer Abstracts at Upcoming 2026 ASCO GI Symposium ... prestigious ASCO symposium with two abstracts," commented Company CEO Uzi Sofer.
Edit

Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium

PR Newswire 02 Dec 2025
... American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) from January 8-10, 2026, in San Francisco ... The majority of abstracts accepted to ASCO GI will be released at 2.00 p.m.
Edit

BullFrog AI Announces Abstract Accepted for Presentation at 2026 ASCO Gastrointestinal Cancers Symposium

Nasdaq Globe Newswire 04 Nov 2025
AI-driven precision-oncology analysis identifies patient subtypes with potential enhanced response to glufosfamide ... .
Edit

Nuvalent to Present Patient-Reported Outcomes Data from ARROS-1 Trial of ROS1-Selective Inhibitor, Zidesamtinib, at 2025 IASLC ASCO North America Conference on Lung Cancer

PR Newswire 04 Nov 2025
... encore pivotal efficacy and safety data from the ARROS-1 trial, during two poster presentations at the 2025 IASLC ASCO North America Conference on Lung Cancer being held December 5-7, 2025 in Chicago.
Edit

ASCO Deploys Diving Vessel For Shah Deniz Underwater Operations In Azerbaijan

MENA FN 28 Oct 2025
(MENAFN - Trend News Agency) BAKU, Azerbaijan, October 27.? The "Akademik Tofiq I?smayilov" diving vessel, part of ASCO, a company under the umbrella of AZCON Holding, has hit the ground running ... .

Article Search

tools
×
×
×
×